Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02631720 · ClinicalTrials.gov registry record
CLAD Phenotype Specific Risk Factors and Mechanisms
A clinical trial, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- 884
- Enrollment target
NCT02631720: Completed study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT02631720 is a clinical trial that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 884 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02631720 has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- 884 participants
- Enrollment target
Study Summary
While many patients experience benefits from transplant, complications such as infections and lung rejection may affect long term survival and quality of life. In this study doctors are looking at a complication called Chronic Lung Allograft Dysfunction (CLAD). CLAD is thought to be chronic rejection of the lung by the immune system and is the leading cause of death after lung transplantation. The purpose of this study is to help doctors determine: * why some people get CLAD and others do not * how patients who get CLAD do after CLAD is diagnosed * how CLAD may affect quality of life
Primary Outcome
First occurrence of either phenotype.
Interventions
- PROCEDURE Bronchoscopy
- PROCEDURE Blood Draw
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 884 participants |
| Start Date | 2015-12-22 |
| Est. Completion | 2019-11-30 |
What the finished NCT02631720 record still lists
NCT02631720 is an observational study that tracks outcomes without assigning an intervention. The registered 884 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 2 interventions - of which Bronchoscopy is the first listed.
NCT02631720 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02631720 about?
NCT02631720 is a clinical study titled "CLAD Phenotype Specific Risk Factors and Mechanisms". While many patients experience benefits from transplant, complications such as infections and lung rejection may affect long term survival and quality of life. In this study doctors are looking at a complication called Chronic Lung Allograft Dysfunction (CLAD). CLAD is thought to be chronic rejectio...
What is the current status of trial NCT02631720?
This trial is currently completed. The enrollment target is 884 participants. The study started on 2015-12-22. Estimated completion is 2019-11-30.
What interventions are being tested in trial NCT02631720?
The interventions under investigation include: Bronchoscopy (PROCEDURE), Blood Draw (PROCEDURE).
Who is sponsoring clinical trial NCT02631720?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07196748 · 882 participants · Phase 3
A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
- NCT05174286 · 880 participants · NA
Community Health Workers United to Reduce Colorectal Cancer and Cardiovascular Disease Among People at Higher Risk
- NCT05454280 · 880 participants · Phase 3
Post-Discharge Risk-Based Management in Patients Undergoing High-Risk Elective Major Cancer Operations (PRS II)
- NCT05525663 · 880 participants · NA
Physical Rehabilitation for Older Patients With Acute Heart Failure With Preserved Ejection Fraction
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI